Clinical Trial Update: Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

View source ↗

Summary

This clinical trial update addresses survival outcomes of EGFR-TKI therapy in patients with uncommon EGFR-mutant advanced non-small cell lung cancer. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR-TKI (unspecified) (epidermal growth factor receptor tyrosine kinase inhibitor)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-small Cell Lung Cancer | Status: RECRUITING